EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 121 filers reported holding EXELIXIS INC in Q2 2013. The put-call ratio across all filers is 0.69 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $10,402,891 | -18.4% | 462,968 | -13.8% | 0.00% | -20.0% |
Q1 2024 | $12,752,170 | -8.9% | 537,386 | -7.9% | 0.01% | 0.0% |
Q4 2023 | $13,993,007 | +20.6% | 583,285 | +9.9% | 0.01% | 0.0% |
Q3 2023 | $11,601,410 | +13.3% | 530,957 | -0.9% | 0.01% | +25.0% |
Q2 2023 | $10,240,074 | +1.4% | 535,849 | +3.0% | 0.00% | 0.0% |
Q1 2023 | $10,099,081 | -8.3% | 520,303 | -24.2% | 0.00% | -20.0% |
Q4 2022 | $11,017,266 | +2.8% | 686,862 | +0.5% | 0.01% | 0.0% |
Q3 2022 | $10,721,000 | -24.2% | 683,750 | +0.6% | 0.01% | -16.7% |
Q2 2022 | $14,147,000 | -21.3% | 679,485 | -14.3% | 0.01% | -14.3% |
Q1 2022 | $17,980,000 | +102.9% | 793,116 | +63.6% | 0.01% | +133.3% |
Q4 2021 | $8,862,000 | -26.2% | 484,807 | -14.7% | 0.00% | -40.0% |
Q3 2021 | $12,012,000 | +31.6% | 568,207 | +13.4% | 0.01% | +25.0% |
Q2 2021 | $9,127,000 | -45.2% | 500,909 | -32.1% | 0.00% | -42.9% |
Q1 2021 | $16,667,000 | +27.5% | 737,812 | +13.3% | 0.01% | +16.7% |
Q4 2020 | $13,074,000 | -24.7% | 651,412 | -8.2% | 0.01% | -33.3% |
Q3 2020 | $17,355,000 | +9.3% | 709,812 | +6.1% | 0.01% | 0.0% |
Q2 2020 | $15,883,000 | +44.9% | 669,045 | +5.1% | 0.01% | +12.5% |
Q1 2020 | $10,963,000 | +20.8% | 636,635 | +23.6% | 0.01% | +60.0% |
Q4 2019 | $9,074,000 | -0.2% | 514,983 | +0.2% | 0.01% | -16.7% |
Q3 2019 | $9,093,000 | -17.8% | 514,183 | -0.7% | 0.01% | -14.3% |
Q2 2019 | $11,063,000 | -9.1% | 517,693 | +1.2% | 0.01% | -12.5% |
Q1 2019 | $12,172,000 | +2.3% | 511,420 | -15.4% | 0.01% | -11.1% |
Q4 2018 | $11,896,000 | -18.2% | 604,800 | -26.3% | 0.01% | -10.0% |
Q3 2018 | $14,551,000 | +59.7% | 821,180 | +93.9% | 0.01% | +66.7% |
Q2 2018 | $9,113,000 | +161.1% | 423,485 | +168.7% | 0.01% | +100.0% |
Q1 2018 | $3,490,000 | -33.2% | 157,580 | -8.3% | 0.00% | -25.0% |
Q4 2017 | $5,222,000 | +24.8% | 171,780 | -0.5% | 0.00% | +33.3% |
Q3 2017 | $4,185,000 | -29.0% | 172,730 | -27.8% | 0.00% | -40.0% |
Q2 2017 | $5,896,000 | -38.2% | 239,380 | -45.6% | 0.01% | -37.5% |
Q1 2017 | $9,540,000 | +36.7% | 440,237 | -6.0% | 0.01% | +33.3% |
Q4 2016 | $6,979,000 | +36.2% | 468,098 | +16.8% | 0.01% | +50.0% |
Q3 2016 | $5,124,000 | +59.8% | 400,663 | -2.4% | 0.00% | +33.3% |
Q2 2016 | $3,206,000 | +95.2% | 410,478 | 0.0% | 0.00% | +200.0% |
Q1 2016 | $1,642,000 | -29.1% | 410,478 | 0.0% | 0.00% | -50.0% |
Q4 2015 | $2,315,000 | +0.5% | 410,478 | 0.0% | 0.00% | 0.0% |
Q3 2015 | $2,303,000 | +53.0% | 410,478 | +2.5% | 0.00% | +100.0% |
Q2 2015 | $1,505,000 | +56.4% | 400,398 | +7.0% | 0.00% | 0.0% |
Q1 2015 | $962,000 | +78.5% | 374,298 | 0.0% | 0.00% | – |
Q4 2014 | $539,000 | -11.1% | 374,298 | -5.5% | 0.00% | -100.0% |
Q3 2014 | $606,000 | -54.9% | 396,198 | 0.0% | 0.00% | 0.0% |
Q2 2014 | $1,343,000 | -4.3% | 396,198 | -0.0% | 0.00% | 0.0% |
Q1 2014 | $1,403,000 | -38.1% | 396,225 | +7.2% | 0.00% | -50.0% |
Q4 2013 | $2,265,000 | +5.3% | 369,498 | 0.0% | 0.00% | 0.0% |
Q3 2013 | $2,150,000 | +27.3% | 369,498 | -0.7% | 0.00% | 0.0% |
Q2 2013 | $1,689,000 | – | 371,919 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |